Loading candles…
Medicamen Biotech Ltd, incorporated in 1993, operates as a research-led pharmaceutical company specializing in the development, manufacturing, and marketing of generic finished dosage formulations, including oncology formulations. The company’s business segments include generic pharmaceutical formulations, oncology formulations, and general pharmaceutical formulations. It serves both domestic and international markets, reaching over 35 countries worldwide, with a strategic emphasis on regulated markets and complex generics in the oncology therapeutic area. Medicamen Biotech Ltd is a subsidiary of Shivalik Rasayan Limited, which holds a 42.99% equity stake. The company is positioned within the pharmaceutical industry and continues to focus on expanding its presence in specialized areas of pharmaceuticals.
This page is a live market overview for MEDICAMEN BIOTECH LIMITED (MEDICAMEQ) on the NSE. As a listed security, MEDICAMEN BIOTECH LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for MEDICAMEQ before placing trades on tick2trade.
As of the latest feed, MEDICAMEQ last traded at ₹319.5 on NSE, up ₹0 (0.00%) from the previous close of ₹319.5. Today's session range is ₹0 – ₹0, against a 52-week band of ₹212.4 – ₹447.65. Traded volume today stands at 20.29K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for MEDICAMEQ in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether MEDICAMEQ is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for MEDICAMEN BIOTECH LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in MEDICAMEQ. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated MEDICAMEQ option chain page linked from this overview.
| To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 27 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 13 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 30 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.